Imatinib mesylate in chronic myelogenous leukemia: a Congolese experience

Q4 Medicine

East African medical journal Pub Date : 2016-10-01 DOI:10.4314/EAMJ.V93I10

E. Omesa, I. Kathure, E. Masini, R. Mulwa, A. Maritim, P. Owiti, K. Takarinda, O. Ogutu, R. Kosgei, T. Galgalo

{"title":"Imatinib mesylate in chronic myelogenous leukemia: a Congolese experience","authors":"E. Omesa, I. Kathure, E. Masini, R. Mulwa, A. Maritim, P. Owiti, K. Takarinda, O. Ogutu, R. Kosgei, T. Galgalo","doi":"10.4314/EAMJ.V93I10","DOIUrl":null,"url":null,"abstract":"Background: Chronic myeloid leukemia is a clonal myeloproliferative disorder caused by reciprocal translocation t(9;22) that induces tyrosin kinase protein. Imatinib is a selective inhibitor of this protein. Objectives: To assess responses to imatinib and outcome of Congolese patients with chronic phase chronic myeloid leukemia. Design: retrospective study. Settings: Clinical Haematology unit of Teaching Hospital in Brazzaville, Congo Subjects: Newly diagnosed patients with chronic phase chronic myeloid leukemia treated with imatinib. Results: A total of 25 males and 14 females with a mean age of 36 years at time of the diagnosis were enrolled in the study. The mean duration of the illness was 11.4 months. Imatinib induced complete hematologic response at 3 months in 100%. Major cytogenetic response was noticed in 87.18%. After a median follow up of 12 months, chronic myeloid leukemia had not progressed to the accelerated or blastic phase in an estimated 91.8% of patients and 86.6% were alive. Conclusion: Imatinib is effective in newly chronic phase chronic myeloid leukemia patient even though cytogenetic response rate are lower in Africa than western countries populations","PeriodicalId":11399,"journal":{"name":"East African medical journal","volume":"33 1","pages":"531-535"},"PeriodicalIF":0.0000,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"East African medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/EAMJ.V93I10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 11

Abstract

Background: Chronic myeloid leukemia is a clonal myeloproliferative disorder caused by reciprocal translocation t(9;22) that induces tyrosin kinase protein. Imatinib is a selective inhibitor of this protein. Objectives: To assess responses to imatinib and outcome of Congolese patients with chronic phase chronic myeloid leukemia. Design: retrospective study. Settings: Clinical Haematology unit of Teaching Hospital in Brazzaville, Congo Subjects: Newly diagnosed patients with chronic phase chronic myeloid leukemia treated with imatinib. Results: A total of 25 males and 14 females with a mean age of 36 years at time of the diagnosis were enrolled in the study. The mean duration of the illness was 11.4 months. Imatinib induced complete hematologic response at 3 months in 100%. Major cytogenetic response was noticed in 87.18%. After a median follow up of 12 months, chronic myeloid leukemia had not progressed to the accelerated or blastic phase in an estimated 91.8% of patients and 86.6% were alive. Conclusion: Imatinib is effective in newly chronic phase chronic myeloid leukemia patient even though cytogenetic response rate are lower in Africa than western countries populations

查看原文本刊更多论文

甲磺酸伊马替尼治疗慢性粒细胞白血病:刚果经验

背景:慢性髓系白血病是一种克隆性骨髓增生性疾病，由诱导酪氨酸激酶蛋白的相互易位引起(9;22)。伊马替尼是这种蛋白的选择性抑制剂。目的:评估刚果(金)慢性期慢性髓性白血病患者对伊马替尼的反应和预后。设计:回顾性研究。背景:刚果布拉柴维尔教学医院临床血液科研究对象:用伊马替尼治疗的新诊断的慢慢期慢性髓性白血病患者。结果:共有25名男性和14名女性被纳入研究，诊断时平均年龄为36岁。平均病程11.4个月。伊马替尼在3个月时100%诱导完全血液学反应。87.18%的患者出现了主要的细胞遗传学反应。中位随访12个月后，估计91.8%的慢性髓性白血病患者未进展到加速期或母细胞期，86.6%的患者存活。结论:尽管非洲的细胞遗传学应答率低于西方国家，但伊马替尼对新慢性粒细胞白血病患者是有效的

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

East African medical journal Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The East African Medical Journal is published every month. It is intended for publication of papers on original work and reviews of all aspects of medicine. Communications bearing on clinical and basic research on problems relevant to East Africa and other African countries will receive special attention. Papers submitted for publication are accepted only on the understanding they will not be published elsewhere without the permission of the Editor-in-Chief